REDHILL B.S.ADR 10/IL-,01 WKN: A1KBQX ISIN: US7574681034 Kürzel: RDHL Forum: Aktien Thema: Hauptdiskussion

jetzt 24,6mio

wo?

Sorry Leute ich bin jetzt komplett ausgestiegen und warte erstmal ab an der Seitenlinie. Ich drücke euch ganz fest die Daumen das es weiter hoch geht.

Habe ich das richtig gelesen das der Pre-Market-Volumen bei über 21m liegt?

Buy order wurde ausgelöst.... Der Stopp loss auch allerdings wieder....

Sieht so aus als hätte das Management vor, noch in diesem Jahr die Gewinnzone zu erreichen. Das ist durchaus positiv. Auch positiv ist, dass Redhill bei Beibehaltung der derzeitigen Verluste (ca. 15 Mio) noch für 3 Jahre Geld hat. Es gefällt mir nicht, dass Redhill ein "zugelassenes GI-Medikament" akquirieren will, dass zusätzlichen Umsatz bringen soll. Was auch nicht so schön ist: Der BetriebsVERLUST ist - bereinigt um die Wertminderung aus Q4/2021 (Aemcolo) um mehr als 1 Mio $ gestiegen.

Hier noch mal ausführlich https://www.streetinsider.com/dr/news.php?id=20245864

Der Text ließt sich definitiv positiv. Denke absolut nicht das wir heute unter 1€ schließen.

Mr. Ben-Asher further remarked: “Turning to R&D, in reliance of promising clinical and other data we generated to date, we expect external funding for much of our promising R&D programs, through grants, industry partnerships and participation in platform studies. COVID-19, included in a broader category of ‘pandemic preparedness’, remains an area of high interest and need for novel oral therapeutics such as RedHill’s candidates. Regulatory feedback on opaganib, supportive of a confirmatory study has provided a pathway to potential opaganib submissions for approval in COVID-19. Most recently, opaganib further exhibited its variant-agnostic credentials by demonstrating potent in vitro efficacy against Omicron, while also showing, in a separate study, potent in vitro inhibition of influenza A H1N1, adding to evidence of opaganib’s broader antiviral potential and its promising applicability to ‘pandemic preparedness’. Meanwhile, RedHill’s 2nd COVID-19 therapeutic candidate, RHB-107, successfully met the Part A study primary outcome measure for its Phase 2/3-stage study in non-hospitalized COVID-19, showing, among other promising data, a 100% reduction in hospitalization due to COVID-19. Discussions are ongoing regarding potential external funding through grants, platform studies and other public, private and industry partnerships to support the opaganib and RHB-107 programs, as well as our ongoing Phase 3 study with RHB-204 for NTM disease.”

Micha Ben Chorin, Chief Financial Officer at RedHill, added: “RedHill’s commercial team has further strengthened Movantik®’s share of the growing PAMORA class to approximately 74%, and Talicia®’s approximately 13% quarterly growth further consolidates its position as the leading U.S. brand for H. pylori eradication. The Company’s disciplined cost control measures reduced Q1/22 cash used in operating activities by more than 70% to approximately $4 million, compared to approximately $15 million in Q4/21. Despite the challenging market conditions, RedHill is on its way to achieving company-wide positive cash from operations1 this year, and this, along with the envisaged growth drivers from the pipeline and potential acquisitions, could boost cash generation and further improve cash flow. We are confident that RedHill is well positioned for continuing growth.”

Mr. Ben-Asher continued: “Improved financial stability resulting from cost savings, a commercial basket including three FDA-approved proprietary drugs, continued prescription growth and healthy sales, improved managed care coverage and the amended credit agreement with HCR, positions RedHill for further growth. To that end, RedHill is in non-binding discussions to acquire a synergetic U.S. FDA-approved, patented GI drug currently generating dozens of millions of dollars, which, if materialized, will help expedite and increase cash generation.”